TSB received a call this weekend from an industry source who told us that there is trouble in paradise at Bacterin. Belgrade, Montana is paradise, isn't it? There were some integral resignations from the executive management team along with multiple sales people resigning. Could this be the beginning of the end? TSB wants to know what our readers have heard on the street?
Remember what Jim Morrison of the Doors once sang:
This is the end, beautiful friend
This is the end, My only friend, the end
It hurts to set you free, But you'll never follow me
The end of laughter and soft lies
The end of nights we tried to die
Cook has never been a straight shooter and deserves whatever he gets. You reap what you sow.
ReplyDeleteThis is not the first time, "integral resignations from the executive management team along with multiple sales people resigning"... has occured.
ReplyDeleteAs long as Bacterin can keep conning people into investing in the company, they can always reload with the next generation of "sales team".
The reason some people can be conned is because some people want something for nothing. Well Bacterin gives them nothing for something.
I would hope Middlebury has a well secured loan. If the company is the collateral, then bring on new management and owners.
Bacterin having to start up yet another generation of their sales force is becoming old news. Please slink away and die.
ReplyDeleteI would like the spine blogger and other industry experts to comment about mesoblast. What do they think of the management and the products for disc regeneration? Is this the future? Or more hype?
ReplyDeleteInvestor presentation from last quarter. SLide 18 forecasts are amazing. Must have the next generation of Infuse.
ReplyDeletewww.wlawson215.com/upload/Bacterin%20Presentation%5B1%5D.pdf
With morale low, inner turmoil, a "me too" product, and a horrible reputation I doubt there will be many future generations for this company. Most of their reps are hanging by a thread, and I hear they will let the next batch go soon for not coming close to the quotas that have been significantly lowered. That doesn't sound at all like a market leader. Maybe I just missed the sarcasm in the prior post.
ReplyDeleteYou missed the sarcasm. He forecasts a sales increase from 6 million to 22 million in one year. I would guess Middlebury is now asking some hard questions and basically asking, show me the money. Kind of like what happend with the last sucke...investors.
ReplyDeleteBored ~
ReplyDeleteTo answer your question about Mesoblast, there is more data needed before we can make a judgement on Mesenchymal Precursor Cells and their ability to regenerate Type I and Type II collagen, aka the spinal disc.
The Company that I believe is leading the chase is ISTO Technologies. They are utilizing juvenile cartilage cells that have been replicated over and over, yet still remain viable. They are immune privilaged cells, just like the MPC's that Mesoblast is using, but the juvenile cells are 100 fold more potent than the adult cells.
Juvenile chondrocytes are of mesenchymal origin and are already pre-programmed to form either Type I or Type II Collagen. They will not diferentiate into something else as they are already down the lineage of a chondrocyte.
It will be an interesting race and to the winner go the spoils.